149 related articles for article (PubMed ID: 23727327)
21. Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients.
Chudecka-Głaz A; Rzepka-Górska I; Wojciechowska I
Eur J Gynaecol Oncol; 2012; 33(4):382-90. PubMed ID: 23091895
[TBL] [Abstract][Full Text] [Related]
22. Ovarian carcinomas express HE4 epitopes independently of each other.
Hellstrom I; Yip YY; Darvas M; Swisher E; Hellstrom KE
Cancer Treat Res Commun; 2019; 21():100152. PubMed ID: 31226514
[TBL] [Abstract][Full Text] [Related]
23. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
24. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.
Huhtinen K; Suvitie P; Hiissa J; Junnila J; Huvila J; Kujari H; Setälä M; Härkki P; Jalkanen J; Fraser J; Mäkinen J; Auranen A; Poutanen M; Perheentupa A
Br J Cancer; 2009 Apr; 100(8):1315-9. PubMed ID: 19337252
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
[TBL] [Abstract][Full Text] [Related]
26. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
28. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
29. Is HE4 a useful endometrioma marker?
Leggieri C; D'Agostino G; Tommasi L; Plebani M; Conte L
Eur J Gynaecol Oncol; 2014; 35(4):438-41. PubMed ID: 25118488
[TBL] [Abstract][Full Text] [Related]
30. The clinical significance of the combined detection of serum Smac, HE4 and CA125 in endometriosis-associated ovarian cancer.
Xu XR; Wang X; Zhang H; Liu MY; Chen Q
Cancer Biomark; 2018 Feb; 21(2):471-477. PubMed ID: 29226858
[TBL] [Abstract][Full Text] [Related]
31. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
32. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
[TBL] [Abstract][Full Text] [Related]
34. HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.
Rowswell-Turner RB; Singh RK; Urh A; Yano N; Kim KK; Khazan N; Pandita R; Sivagnanalingam U; Hovanesian V; James NE; Ribeiro JR; Kadambi S; Linehan DC; Moore RG
J Immunol; 2021 May; 206(10):2478-2488. PubMed ID: 33903172
[TBL] [Abstract][Full Text] [Related]
35. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
36. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.
Granato T; Midulla C; Longo F; Colaprisca B; Frati L; Anastasi E
Tumour Biol; 2012 Oct; 33(5):1335-9. PubMed ID: 22528938
[TBL] [Abstract][Full Text] [Related]
37. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.
Liao JB; Yip YY; Swisher EM; Agnew K; Hellstrom KE; Hellstrom I
Gynecol Oncol; 2015 Jun; 137(3):430-5. PubMed ID: 25866324
[TBL] [Abstract][Full Text] [Related]
38. Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass.
Huang X; Wang Y; He X; Kang F; Luo L; Su Z; Ye H
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115211
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
Moore RG; Miller MC; Eklund EE; Lu KH; Bast RC; Lambert-Messerlian G
Am J Obstet Gynecol; 2012 Apr; 206(4):349.e1-7. PubMed ID: 22301440
[TBL] [Abstract][Full Text] [Related]
40. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]